The Independent
Study Behind
CREGEN.
The European Institute of Medical and Exercise Cognition ran an independent controlled pilot study on CREGEN — with no stake in the outcome. Early results point to better creatine retention and bioavailability than market competitors.
and Exercise Cognition
Barcelona, Spain · EU Registered
EIMEC Had No Stake
in the Outcome.
EIMEC did not create CREGEN. They did not fund CREGEN. They are not affiliated with CREGEN or with KAIST. Their only job was to verify whether the science held up — with their own cohort, their own protocol, their own methodology.
That is what makes the result meaningful. KAIST invented the CGG Amino-Bridge™. EIMEC, an independent EU institution in Barcelona, set out to challenge it. The data matched.
What the Pilot Study Found.
EIMEC tracked creatine across serum, plasma, and urinary markers. The standout result: significantly lower urinary creatine loss versus a competitor — with consistent directional trends toward higher serum and plasma levels. Preliminary data from a small controlled cohort.
CREGEN vs Competitor 1 — Creatine Markers
Mean values per marker (n=2-3 per group · 5 g/day · 15 days). Bars are scaled within each marker pair so the comparison is visible across very different units; exact values are labelled on every bar.
* p=0.028 (statistically significant). Urine-spot creatine was ~56% lower with CREGEN (833.3 vs 1900.0) — less creatine flushed out, better retention. Serum and plasma trended higher (more in circulation) but did not reach significance at this pilot's small sample. Pilot study — preliminary and exploratory; larger studies are needed to confirm.
Scientific Team & Facilities
The EIMEC study was conducted by an independent team of researchers at their Barcelona facilities — no affiliation with CREGEN or KAIST.
How the Study Was Conducted
EIMEC designed its own independent methodology. No shared protocol with KAIST. No access to the original study design. A clean, independent verification.
KAIST Invented It.
EIMEC Verified It.
Different countries. Different populations. Different methodologies. Same conclusion. That is the standard CREGEN holds its science to.
Daejeon, South Korea
-
Developed the CGG Amino-Bridge™ delivery mechanism to improve creatine absorption and bioavailability over standard monohydrate
-
Early research pairing creatine monohydrate with glycine and glutamine to improve absorption and retention
-
Origin of the early/preclinical research behind the CGG Amino-Bridge delivery approach
-
Ranked among Asia's top 5 science and technology universities
Barcelona, Spain · EU Registered
-
Conducted an independent controlled pilot study measuring creatine bioavailability in an EU cohort
-
No financial relationship with CREGEN or Nuderma Group — zero conflict of interest
-
Designed its own study protocol independently — did not replicate the KAIST methodology
-
Pointed in the same direction as the KAIST findings — better creatine retention and bioavailability (preliminary)
Questions About the Study
What exactly did EIMEC measure?
EIMEC measured bioavailability — how much of the creatine in CREGEN actually enters and stays in the bloodstream versus being excreted. They tracked creatine across serum, plasma, clearance, and urinary excretion. The standout result was significantly lower urinary creatine loss versus a competitor (p=0.028), with directional trends toward higher serum and plasma creatine. As a pilot study, the results are preliminary.
What is the difference between KAIST and EIMEC?
KAIST — the Korea Advanced Institute of Science and Technology — is where the CGG Amino-Bridge™ technology was discovered and developed. EIMEC, an independent European institute in Barcelona, ran its own study on a completely separate European population to verify those findings from the outside. One created the science; the other checked it with no conflict of interest.
What does the bioavailability result actually show?
The pilot tracked how much creatine is absorbed and retained versus excreted. CREGEN showed significantly lower urinary creatine loss (p=0.028) and higher serum and plasma levels than a competitor — pointing toward greater systemic bioavailability driven by the CGG Amino-Bridge™ delivery system. Because the sample was small, these are preliminary findings that larger studies are designed to confirm.
Can I request the full study data?
Yes. Full study summaries — covering methodology, cohort demographics, and the complete dataset — are available on request to verified retail partners, healthcare practitioners, and serious customers. Email info@cregenusa.com with your details and we will send access within 2 business days.
Why does an independent validation matter if KAIST already published?
A single study — however rigorous — is one data point. Independent replication by a separate institution, with a different cohort and methodology, is the standard by which science earns trust. EIMEC's corroboration of the KAIST findings means the result was not a statistical outlier, not a Korean-population-specific effect, and not influenced by any shared institutional interest. That is what "validated" means in a scientific context.
Independent.
Transparent.
An independent pilot pointing in a promising direction (preliminary). Try CREGEN for 30 days, or submit the return form for a full refund.